# NADIM (NCT03081689)

> Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03081689
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Spanish Lung Cancer Group
- Conditions: Non Small Cell Lung Cancer
- Interventions: Nivolumab 360 mg; Paclitaxel 200mg/m2; Carboplatin AUC 6
- Enrollment: 46
- Primary outcome: Progression Free Survival

## Indexed commentary on NADIM so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 51
- Podcasts: 10
- YouTube: 9

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nadim-nct03081689

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03081689", "email": "<work email>"}; the inbox owner confirms by the emailed link.